China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2015
October 2015
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National
Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any
fictitious statements, misleading statements, or important omissions carried in this report, and shall take all
responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third Quarter Report of the Company in
person.
Yan Zhigang, person in charge of the Company, head of the accounting works Wei Pingxiao and Zhou Feifei,
accounting body principals (accountant in charge) hereby confirm that the Financial Report of the Third Quarterly
Report is authentic, accurate and complete.
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Section II. Main accounting data and changes of shareholders
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting
error correction or not
□Yes √ No
Current period-end Period-end of last year Increase/decrease
Total assets(RMB) 14,298,937,947.02 12,828,941,540.90 11.46%
Net assets attributable to
shareholders of listed company 5,266,153,764.26 4,764,607,822.09 10.53%
(RMB)
Increase/decrease in
Increase/decrease in
Year-begin to end of comparison with year-
Current period comparison with same
the Period begin to Period-end of
period of last year
last year
Operating revenue (RMB) 6,866,003,376.77 9.30% 19,679,806,543.54 9.98%
Net profit attributable to
shareholders of the listed company 186,753,078.44 17.66% 574,072,330.77 13.52%
(RMB)
Net profit attributable to
shareholders of the listed company
183,019,662.66 20.67% 556,678,816.45 16.96%
after deducting non-recurring gains
and losses(RMB)
Net cash flow arising from
-- -- 408,159,149.92 169.26%
operating activities(RMB)
Basic earnings per share
0.515 17.58% 1.583 5.74%
(RMB/Share)
Diluted earnings per share
0.515 17.58% 1.583 5.74%
(RMB/Share)
Weighted average ROE 3.61% 0.07% 11.46% -2.03%
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
Amount from year-begin to
Item Note
end of the Period
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Mainly refers to the income of
relocation compensation from
Gains/losses from the disposal of non-current asset (including the
4,389,032.17 disposal of investment real estate
write-off that accrued for impairment of assets)
by subsidiary Sinopharm Holding
Liuzhou
Governmental subsidy reckoned into current gains/losses (not
Mainly refers to the various
including the subsidy enjoyed in quota or ration according to
13,640,742.24 specific grants and finance
national standards, which are closely relevant to enterprise’s
discount received in the Period
business)
Mainly because the bad debt of
account receivable for Tibet Naqu
Reversal of impairment reserve for account receivable with
3,273,444.33 Company, which has accrual
separate impairment testing
separately last year has collected
in the Period
Mainly due to the earnings from
render a hosted services by
Income of trustee fee obtained from trust for management 375,000.00 Sinopharm Holding and China
National Pharmaceutical Foreign
Trade Corporation
Mainly because subsidiary
Sinopharm Holding Liuzhou
Other non-operating income and expenditure except for the
2,864,911.21 obtained a relocation rewards and
aforementioned items
out-of-resettlement compensation
due to the removal
Less: impact on income tax 5,055,519.61
Impact on minority shareholders’ equity (post-tax) 2,094,096.02
Total 17,393,514.32 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the
Public --- Extraordinary Profit/loss.
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Statement of the total common shareholders and shares-held of top ten common shareholders
at end of the Period
In Share
Total common shareholders at
15,463
period-end
Shares-held of top ten common shareholders
Amount of Number of share pledged/frozen
Nature of Proportion of Amount of shares
Shareholders restricted shares
shareholder shares held held State of share Amount
held
Sinopharm Group State-owned
51.00% 184,942,291 74,482,543
Co., Ltd. corporate
National Council
Domestic non
for Social
state-owned 2.29% 8,300,000
Security Fund –
corporate
116
China Securities
Domestic non
Finance
state-owned 2.12% 7,704,972
Corporation
corporate
Limited
National Council
Domestic non
for Social
state-owned 2.01% 7,298,555
Security Fund –
corporate
106
HTHK/CMG
FSGUFP-CMG
Overseas
FIRST STATE 1.94% 7,032,720
corporate
CHINA
GROWTH FD
VALUE
Overseas
PARTNERS 1.61% 5,847,103
corporate
CLASSIC FUND
Domestic non
CITIC Securities state-owned 1.38% 5,007,937
corporate
China Life Domestic non
1.17% 4,237,124
Insurance state-owned
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Company Ltd. corporate
－tradition －
general insurance
products -005L-
CT001 Shen
New China Life
Insurance
Company Ltd. Domestic non
－Dividend － state-owned 1.16% 4,199,772
individual corporate
bonuses -018L-
FH002 Shen
China SAFE Domestic non
Investments state-owned 1.05% 3,804,400
Limited corporate
Particular about top ten common shareholders with un-restrict shares held
Type of shares
Shareholders Amount of un-restrict common shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 110,459,748 110,459,748
shares
National Council for Social Security RMB ordinary
8,300,000 8,300,000
Fund – 116 shares
China Securities Finance RMB ordinary
7,704,972 7,704,972
Corporation Limited shares
National Council for Social Security RMB ordinary
7,298,555 7,298,555
Fund – 106 shares
Domestically
HTHK/CMG FSGUFP-CMG FIRST
7,032,720 listed foreign 7,032,720
STATE CHINA GROWTH FD
shares
Domestically
VALUE PARTNERS CLASSIC
5,847,103 listed foreign 5,847,103
FUND
shares
RMB ordinary
CITIC Securities 5,007,937 5,007,937
shares
China Life Insurance Company Ltd.
RMB ordinary
－tradition －general insurance 4,237,124 4,237,124
shares
products -005L-CT001 Shen
New China Life Insurance Company RMB ordinary
4,199,772 4,199,772
Ltd. －Dividend －individual shares
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
bonuses -018L-FH002 Shen
RMB ordinary
China SAFE Investments Limited 3,804,400 3,804,400
shares
Explanation on associated It is unknown that there exists no associated relationship or belongs to the consistent actionist
relationship among the aforesaid among the other tradable shareholders regulated by the Management Measure of Information
shareholders Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement dealing
in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings in Period-end
□Applicable √Not applicable
China National Accord Medicines Corporation Ltd.The Third Quarterly Report for 2015
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
1. Note receivable: cut down by 224.8243 million Yuan over that of opening balance with growth rate of -36.32%,
mainly because the settlement service with trade acceptance reduced in the Period;
2. Other account receivable: increased 28.0236 million Yuan over that of opening balance with growth rate of
98.07%, mainly because the deposit and margin are increased in the Period;
3. Other current assets: cut down by 16.1344 million Yuan over that of opening balance with growth rate of -40.03%,
mainly because the VAT to-be-deducted reduced in the Period;
4. Interest payable: increased 2.1271 million Yuan over that of opening balance with growth rate of 31.91%, mainly
due to the rising financing scale in the Period;
5. Non-current liability due within one year: increased 3.0431 million Yuan over that of opening balance with
growth rate of 76.08%, mainly because corresponding fair value of the Member Points due within one year are
increased over that of period-begin;
6. Long-term loans: increased 30.9984 million Yuan over that of opening balance with growth rate of 78.09%,
mainly due to the newly increased Pingshan Project loans in the Period;
7. Other business income: up 20.0843 million Yuan on y-o-y basis with growth rate of 35.63%, mainly because the
income from offering R&D technical services and sales of material income increased;
8. Other business cost: up 16.3505 million Yuan on y-o-y basis with growth rate of 145.50%, mainly because the
sales material business goes up on y-o-y basis;
9. Non-operation income: dropped 19.8009 million Yuan on y-o-y basis with growth rate of -53.71%, mainly
because in line with the litigation outcome last period, the compensation of lawsuit which accrual from previous
years have been written back, and no such business occurred in the Period;
10. Non-operation expenditure: dropped 1.0394 million Yuan on y-o-y basis with growth rate of -67.56%, mainly
because at same period of last
